SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (6509)6/7/2002 12:54:35 PM
From: nigel bates  Respond to of 52153
 
BTW many months if not a year ago, I posted that Cash Is Trash.
Absolute nonsense, I'm afraid.
If you're a small biotech, a significant wodge of cash is likely to be the difference between survival and otherwise, given the current funding environment.
It you're an investor, cash would have been a very smart hold over the last twelve months.



To: Czechsinthemail who wrote (6509)6/7/2002 1:03:49 PM
From: rkrw  Respond to of 52153
 
My personal rule of thumb is to avoid companies low in cash AND a low share price. Severe dilution kills s/h returns and very few companies climb out of the repetitive cycle of dilutive financings. Any bio that didn't raise substantial funds in the 2000 timeframe (btrn) was incredibly blind imo.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News